Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 trial investigating the effect and safety of afatinib in previously treated
recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR
amplification.